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Sir,
I thank Drs Molina-Garrido and Guille ´n-Ponce (Molina-Garrido
and Guille ´n-Ponce, 2010) for their kind commentaries that we
share almost completely.
It is obvious that, as oncologists, we need a tool that allows us to
identify those elderly patients who are more sensitive to
chemotherapy and are therefore more prone to developing
complications resulting from cancer treatments. Nowadays, it is
considered that comprehensive geriatric assessment (CGA) is more
effective than the standard medical evaluation in the elderly
(Gosney, 2005). This tool was designed to evaluate the following
aspects: functional status, comorbidity, mental status, emotional
conditions, polypharmacy and geriatric syndromes (Balducci and
Extreman, 2000; Rao et al, 2004). The use of this scale allows us to
divide patients into three different groups from a therapeutic point
of view: fit (same treatment strategies as those used in younger
patients), frail (reduced dose or no chemotherapy) and inter-
mediate. Patients of the first two groups are easily classified.
However, the intermediate group is more difficult to identify
(Ko ¨hne et al, 2008). Notwithstanding the multidimensional
character of the CGA scale, only two parameters’ comorbidity
and performance status (measured using the Lawton–Brody scale
and the Barthel scale) are used to distinguish between the fit and
the intermediate groups (Balducci and Extreman, 2000; Ko ¨hne
et al, 2008). We used these two parameters alone because of this
later fact as inclusion. Nevertheless, each investigator could decide
to use the CGA scale following its own criteria or depending on
patient characteristics.
It must be said that even if the CGA scale is a useful tool,
several authors have described some limitations (Carreca et al,
2005): it is not standardised, it is time consuming and it is
fragmentary, thereby impeding a correct global assessment
of the patient. These limitations have prevented its general use.
Therefore, during the last few years, several authors have made an
effort to simplify the CGA scale to transform it into a more
practical tool. However, most of these proposals were developed
after this study was designed. These studies have shown similar
outcomes between the CGA scale and the new tools. Nevertheless,
it is essential to study the capacity of these new tools to identify
vulnerable patients with trials specifically designed for this
purpose.
There is a long road to walk in the field of elderly cancer
patients. Unfortunately, as far as medical oncologists are bad
geriatricians and as geriatricians are not good oncologists, a
multidisciplinary collaboration is necessary to improve the
treatment of elderly patients with cancer.
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